Ultralife Corporation is a global provider of mission-critical battery, power, communications, and computing solutions for demanding applications across government and defense, medical, oil and gas, and industrial markets. Headquartered in Newark, New York, the company operates through two primary segments: Battery & Energy Products and Communications Systems. Its portfolio spans rechargeable and non-rechargeable batteries, battery systems, and related accessories, with differentiated capabilities in multi-chemistry technologies, high energy density, long shelf life, low self-discharge, and cold-weather performance.
Ultralife serves defense and commercial customers worldwide, with operations across North America, Europe, and Asia and a workforce of more than 700 employees. Investors have historically followed the stock for its exposure to military communications power, specialized industrial batteries, and communications electronics. Its purpose-built manufacturing capacity, patent portfolio, and compliance with Foreign Entity of Concern (FEOC) standards are frequently cited competitive strengths in a defense supply chain facing heightened scrutiny. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, ULBI shares have risen approximately +152%, from a closing price of $6.21 to a level near $15.67. The move was not gradual: virtually the entire advance occurred in a single trading session in late October, when the stock re-rated from roughly $6.30 to the mid-$15 range following the acquisition announcement, and it has since traded in a narrow band near the $16.00 offer price.
The quarterly picture tells a similar story. Roughly three months ago the stock was changing hands near $7.01, meaning it has gained about +124% over the quarter. Before the announcement, however, Ultralife shares spent much of the period range-bound, oscillating between the low $5s and low $7s, with notable volatility around earnings-related trading in August and September. The late-October acquisition re-priced the stock sharply upward and has since dominated its technical behavior.
The single dominant catalyst was the October 27 announcement that EnerSys, a global stored-energy solutions company, had entered into a definitive agreement to acquire Ultralife for $16.00 per share in cash. The transaction values Ultralife at roughly $320 million in enterprise value and represented a 166% premium to its unaffected closing price of $6.01 on October 26. The stock responded by surging approximately 145% the following session, with trading volume far exceeding its typical average as arbitrage and event-driven investors entered the name.
The strategic rationale centered on defense power. EnerSys framed the deal as a way to expand its advanced battery portfolio into munitions, soldier power, drones, counter-drone systems, and autonomous platforms, while adding U.S.-based, FEOC-compliant manufacturing capacity. EnerSys expects the combination to generate $15 million to $20 million in annual run-rate cost synergies within the first 18 months and to be accretive to adjusted diluted earnings per share within roughly 18 months of closing. The transaction is funded with cash on hand and is not subject to a financing condition.
For most of the quarter, Ultralife traded as a small-cap industrial and defense supplier, with its share price responding to ordinary earnings cycles, sector sentiment, and broader market conditions rather than any single corporate event. The stock showed meaningful volatility, rising into the mid-$7s in mid-August before drifting back toward the $5.50-to-$6.50 range through September and October. That low-valuation, range-bound backdrop ultimately set the stage for the acquisition premium, which was measured against a depressed pre-announcement price.
The broader narrative over the quarter was one of a company with valuable, specialized defense-oriented battery assets that were not fully reflected in its public-market valuation. The EnerSys agreement crystallized that value for shareholders in a single, decisive repricing, and the stock has since stabilized near the cash offer as investors track progress toward closing.
With the stock now trading near the $16.00 cash offer, the primary variables ahead are transactional rather than operational. Investors are likely to monitor the commencement and progress of the tender offer, the percentage of shares tendered against the majority condition, and the status of regulatory reviews, including U.S. antitrust clearance and the U.K. National Security and Investment Act process. The merger agreement contains a termination fee and an outside date in April 2027, with extension provisions tied to outstanding antitrust conditions.
Key risks include potential delays in obtaining approvals, the possibility of competing proposals, and the standard uncertainties associated with closing conditions. Because the deal would result in Ultralife's delisting upon completion, the stock's near-term trajectory is expected to remain closely tied to the spread between the market price and the offer price. Investors should also monitor Ultralife's underlying business results and any material developments disclosed in SEC filings during the pendency of the transaction. From what I see, this is important because the outcome hinges on regulatory timelines rather than day-to-day operations.
In my view, tools like Tickeron’s AI Trend Prediction Engine can help investors track how acquisition-driven moves align with broader patterns across similar defense and industrial names. I’ve used the platform to review historical performance and compare signals, which adds a layer of data-driven context to the fundamental story here without replacing careful review of the deal terms themselves.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ULBI's Aroon Indicator triggered a bullish signal on November 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 163 similar instances where the Aroon Indicator showed a similar pattern. In 132 of the 163 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 81%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
ULBI moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ULBI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
The 50-day moving average for ULBI moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +0.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ULBI advanced for three days, in 174 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ULBI as a result. In 88 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for ULBI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 41 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ULBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
ULBI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.969) is normal, around the industry mean (2.765). P/E Ratio (-40.154) is within average values for comparable stocks, (13.467). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.910). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (0.487) is also within normal values, averaging (9.055).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ULBI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of dry cell batteries
Industry ElectricalProducts